NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

6 Months Ended

Mar. 31, 2020

Summary of stock options issued and outstanding

Below is a table summarizing the options issued and outstanding as of and for the six months ended March 31, 2020:


				Weighted
		Weighted		Average	Total
		Average		Remaining	Aggregate
		Exercise		Contractual Life	Intrinsic
	Stock Options	Price		(in years)	Value
Outstanding as of September 30, 2019	6,375,966	$	2.70
Granted	136,000		6.20
Forfeited	(5,000)		7.56
Outstanding at March 31, 2020	6,506,966	$	2.77	8.9	$	28,977,799
Exercisable as of March 31, 2020	4,231,799	$	1.34	8.7	$	25,120,498

Schedule of key assumptions used to estimate the fair value of the stock options granted

Key assumptions used to estimate the fair value of the stock options granted during the six months ended March 31, 2020 included:


		Six Months ended
		March 31, 2020
Expected term of options (years)		7.0
Expected common stock price volatility		78% - 83.5%
Risk-free interest rate		0.9% - 1.8%
Expected dividend yield		-

Summary of changes in the outstanding restricted stock

A summary of the changes in the unvested restricted stock during the six months ended March 31, 2020 is as follows:


			Weighted
				Average
	Unvested Restricted		Grant Date
	Stock		Fair Value
Unvested as of September 30, 2019		6,875	$	6.24
Granted		2,752		6.36
Vested		(6,502)		6.29
Unvested as of March 31, 2020		3,125	$	6.24
Total unrecognized expense remaining	$	5,830
Weighted-average years expected to be recognized over		0.2

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations for the three and six months ended March 31,2020 and 2019:


	Three Months Ended March 31,				Six Months Ended March 31,
	2020		2019		2020		2019
			Restated (Note 2)				Restated (Note 2)
General and administrative	$	954,241	$	1,245,414	$	2,067,352	$	1,534,300
Research and development		385,169		8,757		776,284		13,174
Total	$	1,339,410	$	1,254,171	$	2,843,636	$	1,547,474